Arcus Biosciences (RCUS) EBT (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBT of -$128.0 million for Q1 2026, down 14.29% year-over-year from -$149.3 million in Q1 2025, and down 20.75% quarter-over-quarter from -$106.0 million in Q4 2025.
Arcus Biosciences (RCUS) EBT (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBT history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.
- In Q1 2026, EBT fell 14.29% year-over-year to -$128.0 million; the TTM figure through Mar 2026 stood at -$369.0 million (up 5.38% YoY), while the FY2025 annual figure was -$353.0 million, down 25.18% from the prior year.
- EBT for Q1 2026 stood at -$128.0 million, down from -$106.0 million in the prior quarter.
- The five-year high for EBT was -$4.0 million in Q1 2024, with the low at -$135.0 million in Q3 2025.
- The 5-year median for EBT is -$79.0 million (2023), against an average of -$83.1 million.
- The sharpest annual moves came in 2024 and 2025: EBT jumped 94.87% in 2024, then plunged 2700.0% in 2025.
- Arcus Biosciences' EBT stood at -$67.0 million in 2022, then declined by 19.4% to -$80.0 million in 2023, then declined by 16.25% to -$93.0 million in 2024, then decreased by 13.98% to -$106.0 million in 2025, then slipped by 20.75% to -$128.0 million in 2026.
- Business Quant data shows RCUS's EBT at -$128.0 million in Q1 2026, -$106.0 million in Q4 2025, and -$135.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -91.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.00 Mn |
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -106.00 Mn |
| Sep 30, 2025 | -135.00 Mn |
| Mar 31, 2025 | -112.00 Mn |
| Dec 31, 2024 | -93.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | -4.00 Mn |
| Dec 31, 2023 | -80.00 Mn |
| Sep 30, 2023 | -69.00 Mn |
| Jun 30, 2023 | -74.00 Mn |
| Mar 31, 2023 | -78.00 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -67.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 281.54 Mn |
| Sep 30, 2021 | -77.98 Mn |
| Jun 30, 2021 | -75.97 Mn |